RT Journal Article
SR Electronic
T1 Hepatic artery injection of <sup>131</sup>I-metuximab combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective non-randomized, multicenter clinical trial
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.121.262136
DO 10.2967/jnumed.121.262136
A1 Hui Chen
A1 Gang Nan
A1 Ding Wei
A1 Ren-You Zhai
A1 Ming Huang
A1 Wu-Wei Yang
A1 Bao-Cai Xing
A1 Xu Zhu
A1 Hai-Feng Xu
A1 Xiao-Dong Wang
A1 Xiao-Yong Zhang
A1 Bao-Rang Zhu
A1 Peng Liu
A1 Guang Cao
A1 Song Gao
A1 Chun-Yi Hao
A1 Ren-Jie Yang
A1 Jian-Hai Guo
A1 Xin Zhang
A1 Kun Gao
A1 Kun Wang
A1 Jian-Feng Wang
A1 Zi-Yu Li
A1 Lin-Zhong Zhu
A1 Rong Ding
A1 Jing Li
A1 Ling Zhao
A1 Yu-Jun Shao
A1 Hai-Chun Liu
A1 Jie-Lai Xia
A1 Ling Wang
A1 Ling-Ming Kong
A1 Zhi-Nan Chen
A1 Huijie Bian
YR 2021
UL http://jnm.snmjournals.org/content/early/2021/09/02/jnumed.121.262136.abstract
AB This prospective non-randomized, multicenter clinical trial was performed to investigate efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 months in the TACE+131I-metuximab group (n = 160) and 3 months in the TACE group (n = 160) (hazard ratio, 0.55; 95% confidence interval, 0.43 to 0.70; P &lt; 0.001). The median overall survival was 28 months in the TACE+131I-metuximab group and 19 months in the TACE group (hazard ratio, 0.62; 95% confidence interval, 0.47 to 0.82; P = 0.001). Conclusion: TACE+131I-metuximab showed a greater anti-recurrence benefit, significantly improved the 5-year survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients.